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In 2004, the National Department of Health (NDoH) rolled out 
South Africa (SA)’s first Comprehensive HIV and AIDS Care, 
Management and Treatment (CCMT) programme.[1] The initial 
CCMT was later extended in the HIV, AIDS and sexually transmitted 
diseases national strategic plan (NSP) to reduce HIV incidence 
by 50% during the period 2007 - 2011.[2] Later, NSP goals for 
2012 - 2016 aimed to expand access to treatment, care and support 
further to 80% of eligible patients, while reducing the rate of new 
HIV infections and HIV-associated maternal mortality by 50% and 
new HIV infections in children by 90%.[3] The CCMT programme 
has grown considerably since 2004, with declines in new HIV 
infections reported.[3-5] However, recent data reveal that despite these 
advances, SA still has a considerable burden of HIV disease and other 
challenges to overcome.
Since the inception of the CCMT programme, absolute CD4 
T-lymphocyte counts have been used to establish baseline levels of 
immunosuppression in HIV-positive patients and identify those 
eligible for initiation onto antiretroviral therapy (ART), as well as 
for laboratory monitoring of patients on ART.[6] In SA, a network of 
~60 CD4 testing facilities in the National Health Laboratory Service 
(NHLS) have provided ~3.6 million CD4 tests per annum to >3 000 
NDoH health facilities (hospitals and clinics). These data sets are 
collated nationally through the NHLS Corporate Data Warehouse 
(CDW).
During the period 2004 - 2015, the NHLS provided >32 million 
CD4 tests in support of the CCMT programme. Cumulative and 
annualised CD4 laboratory test volume data linked to the districts/
provinces where the tests were ordered (but not necessarily where 
patients live) provide important insights into and information about 
the relative HIV disease burden. Marked immunosuppression can be 
characterised by CD4 counts <100 cells/μL, and HIV-positive patient 
‘wellness’ by the distribution of CD4 counts >500 cells/μL.
Objective
To document the distribution and percentages of severely 
immunosuppressed HIV-positive patients, as well as the percentages 
of recovering and treated patients with CD4 counts >500 cells/µL, 
overall across SA’s nine provinces and in the context of the country’s 
52 districts.  
Methods
CD4 data were extracted from the NHLS CDW to establish a baseline 
(2010/11) with which 2014/15 outcomes could be compared. Data 
were analysed using Microsoft Excel and Stata 12. National averages 
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districts had >10% of CD4 samples with counts <100 cells/µL, decreasing to only 17/52 districts by 2014/15. Overall, districts in the Western 
Cape and KwaZulu-Natal had the lowest percentages of CD4 counts <100 cells/µL, as well as the highest percentages of counts >500 cells/µL. 
In contrast, in 2014/15, the highest percentages of CD4 counts <100 cells/µL were noted in the West Rand (Gauteng), Vhembe (Limpopo) 
and Nelson Mandela Bay (Eastern Cape) districts, where the lowest percentages of counts >500 cells/µL were also noted.
Conclusions. The percentages of CD4 counts <100 cells/µL highlighted here reveal districts with positive change suggestive of programmatic 
improvements, and also highlight districts requiring local interventions to achieve the UNAIDS/SA National Department of Health 
90-90-90 HIV treatment goals. The study further underscores the value of using NHLS laboratory data, an underutilised national resource, 
to leverage laboratory test data to enable a more comprehensive understanding of programme-specific health indicators.
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were established for CD4 ranges <100 cells/µL, 100 - 200, 201 - 350 
and 351 - 500 cells/µL and >500 cells/µL, after which the percentages 
of results with reported CD4 counts <100 and >500 cells/µL, 
categorised by province and district for the the years 2010/11 and 
2014/15, were assessed. District boundaries data were downloaded 
from the demarcation board web page (http://www.demarcation.org.
za) and uploaded to ArcGIS software (version 10.2, Esri, USA) to 
enable district boundaries to be defined, including the highlighting 
of prioritised National Health Insurance (NHI) pilot districts. 
Health district percentages for CD4 counts <100 and >500 cells/µL 
were captured in ArcGIS and subsequently mapped using quintile 
graduated colour function in ArcGIS to define bins by district. Bins 
defined included seven for CD4 <100 cells/µL (2010/11) with a range 
of 7.7 - 19.9% in increments of 2%. For 2014/15 data, similar bins 
were created for a range of 6.3 - 13.9%, also in increments of 2%. For 
CD4 counts >500 cells/µL (2014/15), only four bins were created for 
a range of 30.5 - 50% with increments of ~5%.
Results
National, provincial and district averages were compiled from 
3.5 million data points in 2010/11 and 3.9 million data points in 
2014/15.
Analysis of percentages of patients within specified  
CD4 ranges, overall and across provinces
The percentages of patients with CD4 counts in the ranges of <100, 
101 - 200, 201 - 350, 351 - 500 and >500 cells/μL in the financial years 
2010/11 and 2014/15 are set out in Table 1, according to province. 
Percentages of patients with higher CD4 counts increased across the 
country from 2010/11 to 2014/15, with higher percentages of patients 
with CD4 counts >350 or >500 cells/μL noted across all provinces. 
Overall there was less evidence of immunosuppression (CD4 count 
<100 cells/µL) by 2014/15; in 2010/11 the national average was noted 
to be 12.47% v. an average of 9.69% by 2014/15 (a 22% decrease over 4 
years). In this latter group, the percentage of patients with CD4 counts 
between 100 and 200 cells/μL decreased by 50% between 2010/11 
and 2014/15, while a 25% reduction was noted in the percentage of 
patients whose CD4 counts fell into the ‘severely immunosuppressed’ 
group, i.e. <100 cells/μL (Table 1). The national percentage of patients 
with a CD4 count >500 cells/µL increased dramatically by 57% from 
an average of 23.19% in 2010/11 to 36.47% in 2014/15. Further details 
on the changes at provincial level can be seen in Table 1.
Analysis of percentages of patients with CD4 counts 
<100 cells/μL, by district
The percentages of immunosuppressed patients (CD4 count 
<100 cells/µL) are shown in the context of 52 districts for the years 
2010/11 and 2014/15 in Figs 1 and 2 (A and B).
Fig. 1 shows the distribution of percentages of CD4 counts 
<100  cells/µL, per district grouped by province for 2010/11. These 
data sets indicate that almost half the districts (24/52) were above the 
national average of 12.3%. Twenty-nine of 52 districts had a figure 
of >12% in the same time frame, with the highest district percentage 
noted (Greater Sekhukune in Limpopo Province (LP)) at 18.9%. 
Although the national average percentage of CD4 counts <100 cells/
µL fell to 9.7% in 2014/15, only 26 of 52 districts managed to reduce 
the percentage of immunosuppressed patients. This leaves 17 districts 
with a percentage higher than the national average. The highest 
percentage noted in 2014/15 in a district was 13.0% (West Rand, 
Gauteng Province (GP)). A better appreciation of the decrease in the 
district average percentages of CD4 counts <100 cells/µL over time 
can be seen in Fig. 2 (A and B), where colour-graded bins are used.
In 2010/11, the majority of districts (44/52) had individual 
average percentages of CD4 counts <100 cells/µL that exceeded 
10%. Greater Sekhukune district had the highest percentage of CD4 
counts <100  cells/µL, exceeding 18%, while three districts had a 
percentage of >16% (West Rand in GP, Capricorn and Waterberg in 
LP). Ten more districts had percentages of CD4 counts <100 cells/
µL between 14% and 16% (these were Chris Hani and Joe Gqabi 
districts in the Eastern Cape (EC), Lejweleputswa in the Free State 
(FS), City of Johannesburg Metro, Tshwane Metro, Ekurhuleni Metro 
and Sedibeng districts in GP, Vhembe in LP and Gert Sibande and 
Nkangala in Mpumalanga Province (MP)). Higher percentages of 
CD4 counts <100 cells/µL were not limited to rural areas, but were 
noted in urban areas as well, with figures of 12 - 14% and 10 - 12% 
being noted in 15 districts each (Fig. 1 (insert) and Fig. 2 (A)). The 
districts with the lowest percentages of CD4 counts <100 cells/µL 
in 2010/11 were Eden and Overberg in the Western Cape (WC) at 
7.7% and 7.9%, respectively. Six districts had an average percentage 
of <10%; these included districts from WC (Cape Winelands, Cape 
Town Metro, West Coast), KZN (Ilembe and Uthukela) and FS 
(Motheo).
A marked overall positive shift was noted by 2014/15, when no 
district had a >14% average percentage of CD4 counts <100 cells/µL 
(Figs 1 and 2 (B)). Overall, districts with a percentage of CD4 counts 
Table 1. Summary of distribution of the percentages of patients with reported CD4 ranges (cells/µL) for the financial years 2010/11 
and 2014/15
Province
Average percentage of CD4 counts for 2010/11 (2014/15)
<100 101 - 200 201 - 350 351 - 500 >500
Eastern Cape 13.02 (9.55) 16.52 (10.86) 27.52 (20.99) 19.91 (22.16) 23.03 (36.44)
Free State 11.97 (9.60) 16.61 (10.81) 28.42 (21.19) 20.15 (22.15) 22.85 (36.25)
Gauteng 14.99 (11.55) 17.14 (11.38) 28.28 (20.91) 19.02 (21.51) 20.57 (34.66)
KwaZulu-Natal 11.15 (7.33) 15.00 (9.06) 27.21 (20.19) 20.74 (23.30) 25.90 (40.12)
Limpopo 15.62 (11.82) 17.34 (11.58) 27.08 (21.08) 18.57 (20.94) 21.38 (34.58)
Mpumalanga 13.22 (10.15) 16.26 (11.36) 27.54 (22.07) 19.57 (22.29) 23.40 (34.13)
North West 11.51 (10.36) 16.23 (11.12) 28.51 (20.62) 20.65 (21.52) 23.10 (36.39)
Northern Cape 11.85 (9.10) 16.56 (11.3) 28.10 (21.02) 20.40 (21.54) 23.08 (37.03)
Western Cape  8.87 (7.82) 14.67 (10.38) 29.05 (20.45) 22.04 (22.76) 25.37 (38.60)
National average 12.47 (9.69) 16.26 (10.87) 27.97 (20.95) 20.12 (22.02) 23.19 (36.47)
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<100 cells/µL >10% had reduced substantially, declining four-fold 
over 5 years from 44/52 (84.6%) in 2010/11 to 17/52 (33%) by 
2014/15 (Fig. 2 (B)). There was a dramatic increase in the number 
of districts with a lower percentage of CD4 counts <100 cells/µL 
(<10%), from 8 in 2010/11 to 35 in 2014/15. Only four districts had 
percentages of CD4 counts <100 cells/µL between 12% and 14% 
in 2014/15, including West Rand, City of Johannesburg, Nelson 
Mandela Bay (EC) and Vhembe (Table 1 and Fig. 2 (B)). Thirteen 
districts had an average percentage of CD4 counts <100 cells/µL 
between 10% and 12% in 2014/15, including four districts in LP 
(Capricorn, Greather Sekhukhune, Mopani, Waterberg), three in GP 
(Bojanala, Tshwane Metro, Ekurhuleni), two each in MP (Ehlanzeni, 
Nkangala) and North West (NW) (Dr Kenneth Kaunda and Fezile 
Dabi) and one each in FS (Lejweleputswa) and EC (Chris Hani). By 
2014/15, KZN had the lowest recorded percentage of CD4 counts 
<100 cells/µL, noted in Umkhanyakude district (5.4%). The majority 
of KZN districts (9/11) showed a remarkable decrease in percentages 
of CD4 counts <100 cells/µL, with a mean of 7.3% in 2014/15.
Although there is evidence that some districts had a marked 
reduction in the percentage of immunosuppressed patients over the 
5 years since 2010, 32/52 districts showed only modest change over 
the same period, reducing by 1 - 4 percentage points (see Fig. 1 for 
details). By 2014/15, the largest reduction in the percentage of CD4 
counts <100 cells/µL was noted in Greater Sekhukhune district in 
LP, where a 7 percentage points reduction occurred, from 18.9% 
to 11.8%. Other districts that showed reductions of >5 percentage 
points included five in KZN (Ethekwini Metro, Umkhanyakude, 
Ugu, Nkangala, Zululand), two in EC (Joe Gqabi and OR Tambo), 
GP (Sedibeng and Ekurhuleni) and LP (Waterberg and Capricorn), 
and one in MP (Gert Sibande). Five districts showed no change in 
the percentage of CD4 counts <100 cells/µL over time, i.e. Nelson 
Mandela Bay in EC, Motheo in FS, Dr Kenneth Kaunda in NW and 
Eden and Overberg in WC. A negative trend was documented for a 
single district, Mopani, in LP (minus 1 percentage point).
NHI pilot districts (n=11) are highlighted in Fig. 2 (A and B). 
In 2010/11, the majority of NHI districts had a percentage of CD4 
counts <100 cells/µL exceeding 14%. By 2014/15, only Vhembe 
district showed an average percentage of CD4 counts <100 cells/µL 
>12%, with the rest reporting percentages <10%. A sub-analysis of 
NHI v. non-NHI districts showed similar responses over time.
Analysis of percentages of patients with CD4 counts 
>500 cells/μL, by district
Fig. 3 shows the percentages of patients with CD4 counts >500 cells/
μL, by district. Generally, districts with lower percentages of CD4 
counts <100 cells/µL matched with districts with higher percentages 
of counts >500 cells/µL, both for 2010/11 and 2014/15 (Figs 3 and 
4), i.e. an inverse relationship was noted. Correlation of regression 
analysis confirmed a strong significant relationship overall between 
CD4 counts <100 and >500 cells/µL (Spearman non-parametric 
r=–0.82; p<0.0001). As with the CD4 <100 cells/µL data, there is 
evidence of changes in the percentages of CD4 counts >500 cells/μL 
over the 5-year study period, with the highest proportions of counts 
>500 cells/µL noted in KZN and WC during 2014/15. However, not 
all districts showed the same inverse relationship between a decline 
in CD4 counts <100 cells/μL and an increase in counts >500  cells/
μL. Fig. 4 incorporates this information in the context of the per cen-
tage of severely immunosuppressed patients (CD4 <100 cells/µL) to 
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Fig. 1. Graphical summary of the average percentage of samples with CD4 counts <100 cells/μL, per district, grouped by province, for 2010/11 and 2014/15. 
Darker blue bars represent the 2010/11 data and lighter blue bars the 2014/15 data. The national average percentage of CD4 counts <100 cells/μL is indicated 
for 2010/11 at 12.3% (solid green line) and for 2014/15 at 9.4% (solid red line). The insert summarises the number of districts with a percentage of CD4 
counts <100 μL per category, for 2010/11 and 2014/15. (EC = Eastern Cape; FS = Free State; GP = Gauteng Province; KZN = KwaZulu-Natal; LP = Limpopo 
Province; MP = Mpumalanga Province; NW = North West; NC = Northern Cape; WC = Western Cape.)
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reveal the relationship between the percent-
age of CD4 counts >500  cells/µL (y-axis) 
and the percentage of counts <100 cells/µL 
(x-axis), high lighting districts that are cur-
rently below the national average reported 
for 2014/15.
Fig. 4 illustrates the relationship between 
the percentage of CD4 counts <100 cells/μL 
and that of counts >500 cells/μL in quadrants. 
The best-case scenario (Q1) represents 
districts where the percentage of CD4 counts 
>500 cells/μL was highest and the percentage 
of counts <100 cells/μL lowest. Districts that 
fulfil these criteria are nine in KZN, five in 
WC, two in FS, three in EC, two in NC and 
one in NW. Q2 represents districts where 
the percentage of CD4 counts <100 cells/
μL was above the national average, but in 
contrast the percentage of counts >500 was 
also above the national average, including 
Buffalo City Metro (EC), Sedibeng (GP), 
Mangaung (FS), Frances Baard (NC) and 
Dr Kenneth Kaunda (NW). Q3 represents 
districts with the highest percentage of 
CD4 counts <100  cells/μL and the lowest 
percentage of counts >500  cells/µL and 
includes 19 districts in seven provinces. 
These are LP (n=5 districts), GP (n=4), 
MP (n=3), NW (n=2), FS (n=2), EC (n=2) 
and NC (n=1). Most of the Q3 districts 
were in LP, including Vhembe (CD4 count 
<100 cells/μL 12.8% and >500 cells/μL 
30.5%), Greater Sekhukhune (11.8% and 
36.2%, respectively), Capricorn (11.6% and 
36.5%), Mopani (11.6% and 33.6%) and 
Waterberg (11.3% and 36.2%) (Fig. 4). This 
quadrant Q4 represents districts where the 
percentage of CD4 counts <100   cells/μL 
was below the national average, but the 
percentage of counts >500 cells/μL was 
also below the national average (not in 
keeping with the national trend). Q2 and 
Q4 therefore represent districts where the 
inverse relationship between CD4 <100 
and CD4 >500 cells/µL does not follow 
overall national trends, indicating a higher 
percentage of immunosuppression and/or a 
lower percentage of CD4 values exceeding 
the 500 cells/μL level (considered to imply 
wellness).
Discussion
Travis et al.[7] explain that in the attempt to 
overcome health systems constraints neces-
sary to achieve the Millennium Development 
Goals, focus on disease priority in the health 
context has left key areas such as workforce, 
drug supply, health financing and informa-
tion systems under-resourced. They further 
describe the lack of generation and use 
of information for monitoring systems as 
a major barrier to solving priority health 
problems.[7] SA is unique in having the CDW 
held by the NHLS, which enables both col-
lection and use of vital laboratory-related 
health data.
SA is one of the first countries in Africa 
to adopt universal test and treat (UTT) in 
accordance with the 2016 World Health 
Organization guidelines[8] and the UNAIDS 
90-90-90 targets.[9] In a recent NDoH cir-
cular[10] (September 2016), eligibility cri-
teria for UTT clearly state that baseline 
monitoring of the CD4 count is the ‘key 
factor in determining fast-tracking and 
prioritization of patients with CD4 <350 and 
CD4 <200 cells/µl into care’, and eligibility 
for opportunistic infection prophylaxis is 
defined as a CD4 count of <200 cells/µL 
and that for cryptococcal disease screening 
at <100 cells/µL.[6,10] The NHLS CDW is 
an invaluable health data repository that 
can be unlocked to provide information 
to address gaps and guide interventions in 
local health services. The data presented in 
this article specifically focus on the group 
of HIV-positive patients with CD4 counts of 
<100 cells/µL, mapped by district to indicate 
severe immunosuppression.
Since 2004, the NDoH has achieved 
prog ress in the CCMT programme. Initial 
reports revealed an average CD4 count of 
individuals presenting for HIV counselling 
and treatment (HCT) of <200 cells/μL,[4] 
but counts have risen steadily since com-
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Fig. 2. Maps reflecting HIV disease burden as percentages of samples with CD4 counts <100 cells/μL in 
the context of 52 districts in South Africa, in 2010/11 (A) and 2014/15 (B). National Health Insurance 
districts are highlighted with blue borders.
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mencement of the programme, increasing 
to 271 cells/µL in 2014.[11] In line with these 
trends, data reported here confirm an overall 
decrease in the proportion of patients with a 
CD4 count <100 cells/µL of 2.8 percentage 
points (effective as a 22% improvement) over 
5 years. However, despite this progress, ~11% 
of all patients nationally still had CD4 counts 
<200 cells/µL in 2014/15 (Table 1). This is 
in line with other published data indicating 
that a significant number of patients con-
tinue to initiate ART late,[11] despite changes 
in threshold guidelines and scaling up of 
national HIV programmes. Additional data 
reported here further confirm a significant 
increase in the percentage of patients with 
CD4 counts >500 cells/µL (13% increase), 
with an overall inverse relationship to the 
decline in counts <100 cells/µL. CD4 group 
intervals in the <200, <350 and <500 cells/µL 
showed a similar trend, i.e. an increase in the 
percentages of patients with higher CD4 
 
 
 
CD4 counts 
>500 cells/µL, 
2015, %
Fig. 3. Map reflecting the proportion of samples with CD4 counts >500 cells/μL, as percentages of the 
annual total CD4 volumes shown per district for 2014/15. NHI districts are highlighted with blue borders.
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counts, from 2010/11 to 2014/15 (Table 1 and Fig. 1). This may reflect 
better uptake, earlier enrolment into care and patients responding 
better to treatment, although it was out of the scope of this study to 
report on programmatic parameters.
Analysing data at a district level (Figs 1 - 4) added important 
information that was masked by national or provincial averages 
reported. Firstly, district-by-district performance was not consistent 
during the 5-year study period, but this could perhaps be expected, 
considering that the same performance cannot be expected across 
all districts or provinces. This approach allows for localised response 
and customisation of HIV programmes[7] and maintaining focus 
by targeting local needs while still taking into consideration the 
broader health system context. In some districts there was a dramatic 
reduction in the percentage of patients with CD4 counts <100 cells/µL, i.e. 
5 - 7 percentage point reductions were noted in 8/52 districts (including 
Greater Sekhukhune at 7.1%). Gert Sibande and Ethekwini also 
showed a 5 - 6 percentage point reduction in CD4 counts <100 cells/
µL. Three districts (Eden, Dr Kenneth Kaunda and Mopani), 
however, showed an increase in the percentage of counts <100 
cells/μL during the 5-year period. Although most districts matched 
the CD4 <100 cell/µL average of the parent province, in others a 
marked contrast to provincial percentages was noted, emphasising 
the importance of contextual interpretation of local HCT and 
CCMT initiatives (Figs 1 - 4) in any given district. This highlights 
the importance of the inclusion of district and sub-district data 
to successfully identify target problem areas. Underlying reasons/
root causes can then be identified and addressed (Figs 1 and 4), 
including HCT, earlier enrolment into care and long-term therapy 
compliance. Fig. 4 shows the areas where focused attention is urgently 
required (Q3), in which the burden of severely immunosuppressed 
patients (CD4 <100 cells/µL) is highest. Districts that reported 
no change in the percentage of immunosuppressed patients (CD4 
<100  cells/µL) over the 5-year period were Dr Kenneth Kaunda 
(NW), Eden (WC), Mangaung (FS), Nelson Mandela Bay Metro 
(EC) and Overberg (WC). In the Alfred Nzo district, the percentage 
of immunosuppressed patients (CD4 <100 cells/µL) increased from 
10.8 to 11.6% across the 5-year period. In contrast, the dramatic 
changes seen in the remote district of Umkhanyakude in KZN (where 
the percentage of patients with CD4 counts <100 cells/µL was only 
5.4% and the percentage of patients with counts >500 cells/µL >50% 
in 2014/15) should serve as a beacon of hope and testimony to the 
success of local/provincial CCMT initiatives.[12,13]
While district and provincial NDoH activities have played a 
significant role, SA health and related statistics for 2016 may 
offer insights into other factors that could have contributed to the 
dramatic improvement noted in districts across KZN, such as that in 
Umkhanyakude.[13] This 2016 report reveals that, although KZN has 
the highest antenatal prevalence of HIV infection in SA, the province 
also has the highest number of hospital beds and medical personnel 
as well as the highest spend on laboratory servicing.[13] Furthermore, 
KZN is one of two provinces with the highest HIV testing coverage, 
KZN and LP reporting that 39.0% and 40.8%, respectively, of adults 
aged 15 - 49 years were tested for HIV in 2013/14.[13] The data 
reported in our article correspond to those of Day et al.[13] in the 
South African Health Review in that KZN districts had the lowest 
percentages of CD4 counts <100 cells/µL. Day et al.[13] also reported 
that the two provinces with the poorest HIV testing coverage were FS 
and GP, at 26.2% and 23.3%, respectively; our findings are consistent 
with these figures in that GP had two of three districts with the 
highest percentages of immunosuppressed patients (CD4 <100 cells/
µL) and the lowest percentages of patients with CD4 counts >500 cells/
µL nationwide. A platform for sharing lessons learned and systems 
used in districts that have shown improvement over time could offer 
help and insights to assist translation of best practices into other 
districts where little improvement has been noted. Such an approach 
could improve outcomes in districts where a marked burden of 
disease still exists, and facilitate their alignment with the NSP and the 
UNAIDS/NDoH 90-90-90 strategy.[3,9]
Finally, the data presented here and outcomes noted at district 
level, highlighting those areas across SA where the percentage 
of patients with CD4 counts <100 cells/µL is high, should be 
considered in the light of CD4 categories[10] currently used by the 
NDoH to prioritise or fast-track patients into care. HIV patients 
with CD4 counts <100 cells/µL are severely immunosuppressed, 
urgently requiring enrolment into care. Through the national NHLS 
CD4 service, this group is currently automatically screened for 
the presence of cryptococcal antigen (CrAg)[6,10] to identify HIV-
positive immunosuppressed patients with early cryptococcal disease 
before they progress to meningitis. The CrAg results are reported to 
health facilities via the NHLS HIV dashboard on a weekly basis as 
‘results for action’ (RFA),[14] to enable prompt patient follow-up and 
antifungal treatment; immediate enrolment onto ART should also 
be a priority. The NHLS RFA system also enables health facilities to 
be notified about HIV-positive patients with CD4 counts <100 cells/
µL, who in our opinion should be considered as medical emergencies 
requiring urgent enrolment onto ART. Formal acknowledgement of 
this specific category of patients by the NDoH is required to enable 
action at clinic level and ultrafast tracking of this group of patients 
into care.
Study limitations
The CD4 laboratory data used in this study do not distinguish 
between first-ever and follow-up CD4 tests, and may include both 
ART-naive patients and those already on ART, or patients with 
higher CD4 counts not yet enrolled onto ART. The study did 
not investigate underlying factors that could contribute to higher 
percentages of CD4 counts <100 cells/µL (and lower percentages of 
counts >500  cells/µL), such as CD4 recovery over time, adherence 
or retention in HIV care. The study merely aimed to report the 
distribution of immunosuppressed individuals across 52 districts in 
an effort to identify hot spots for programmatic intervention, and it 
was not in its scope to assess cohorts.
Conclusions
The collation of NHLS CDW CD4 data provided important insights 
into HIV disease burden, i.e. immunosuppression (CD4 <100 cells/
µL) and patients with CD4 counts >500 cells/µL. The latter could 
indicate baseline results for patients not yet on treatment (see ‘Study 
limitations’) or response to ART. Analysis of CD4 counts <100 cells/
µL overall, together with a review of the percentages of patients with 
counts >500 cells/µL, by province and by district, showed a positive 
shift over time (a decrease in the percentage of CD4 counts <100 cells/
µL and an increase in counts >500 cells/µL) and identified districts 
that may require urgent interventions to lower their percentage 
of counts <100 cells/µL. The study underscores the value of using 
laboratory data for identifying areas with higher priority needs for 
programmatic intervention.
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